Literature DB >> 28540535

Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.

J Cacicedo1, I Fernandez2, O Del Hoyo3, A Navarro4, A Gomez-Iturriaga3, J Ignacio Pijoan5,6, L Martinez-Indart5, J Escudero5, J Gomez-Suarez7, R Ortiz de Zarate8, J Fernando Perez8, P Bilbao3, D Rades9.   

Abstract

PURPOSE/
OBJECTIVES: To evaluate the prognostic impact of maximum standardized uptake value (SUVmax) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) undergoing pretreatment [F-18] fluoro-D-glucose-positron emission tomography/computed tomography (FDG PET/CT) imaging. MATERIALS/
METHODS: Fifty-eight patients undergoing FDG PET/CT before radical treatment with definitive radiotherapy (±concomitant chemotherapy) or surgery + postoperative (chemo)radiation were analyzed. The effects of clinicopathological factors (age, gender, tumor location, stage, Karnofsky Performance Status (KPS), and treatment strategy) including primary tumor SUVmax and nodal SUVmax on overall survival (OS), disease-free survival (DFS), locoregional control (LRC), and distant metastasis-free survival (DMFS) were evaluated. Kaplan-Meier survival curves were generated and compared with the log-rank test.
RESULTS: Median follow-up for the whole population was 31 months (range 2.3-53.5). Two-year OS, LRC, DFS and DMFS, for the entire cohort were 62.1, 78.3, 55.2 and 67.2%, respectively. Median pretreatment SUVmax for the primary tumor and lymph nodes was 11.85 and 5.4, respectively. According to univariate analysis, patients with KPS < 80% (p < 0.001), AJCC stage IVa or IVb vs III (p = 0.037) and patients undergoing radiotherapy vs surgery (p = 0.042) were significantly associated with worse OS. Patients with KPS < 80% (p = 0.003) or age ≥65 years (p = 0.007) had worse LRC. The KPS < 80% was the only factor associated with decreased DFS (p = 0.001). SUVmax of the primary tumor or the lymph nodes were not associated with OS, DFS or LRC. The KPS < 80% (p = 0.002), tumor location (p = 0.047) and AJCC stage (p = 0.025) were associated with worse cancer-specific survival (CSS). According to Cox regression analysis, on multivariate analysis KPS < 80% was the only independent parameter determining worse OS, DFS, CSS. Regarding LRC only patients with IK < 80% (p = 0.01) and ≥65 years (p = 0.01) remained statistically significant. Nodal SUVmax was the only factor associated with decreased DMFS. Patients with a nodal SUVmax > 5.4 presented an increased risk for distant metastases (HR, 3.3; 95% CI 1.17-9.25; p = 0.023).
CONCLUSIONS: The pretreatment nodal SUVmax in patients with locally advanced HNSCC is prognostic for DMFS. However, according to our results primary tumor SUVmax and nodal SUVmax were not significantly related to OS, DFS or LRC. Patients presenting KPS < 80% had worse OS, DFS, CSS and LRC.

Entities:  

Keywords:  FDG PET; Head and neck cancer; Radiotherapy; Standardized uptake value (SUV)

Mesh:

Substances:

Year:  2017        PMID: 28540535     DOI: 10.1007/s12094-017-1674-6

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  41 in total

Review 1.  Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis.

Authors:  Kyoungjune Pak; Gi Jeong Cheon; Hyun-Yeol Nam; Seong-Jang Kim; Keon Wook Kang; June-Key Chung; E Edmund Kim; Dong Soo Lee
Journal:  J Nucl Med       Date:  2014-04-21       Impact factor: 10.057

2.  Prognostic value of 18F-FDG PET metabolic parameters in oropharyngeal squamous cell carcinoma.

Authors:  Adam A Garsa; Albert J Chang; Todd Dewees; Christopher R Spencer; Douglas R Adkins; Farrokh Dehdashti; Hiram A Gay; Wade L Thorstad
Journal:  J Radiat Oncol       Date:  2013-03

3.  Clinical usefulness of [18F] fluoro-2-deoxy-D-glucose uptake in 178 head-and-neck cancer patients with nodal metastasis treated with definitive chemoradiotherapy: consideration of its prognostic value and ability to provide guidance for optimal selection of patients for planned neck dissection.

Authors:  Haruo Inokuchi; Takeshi Kodaira; Hiroyuki Tachibana; Tatsuya Nakamura; Natsuo Tomita; Rie Nakahara; Akinori Takada; Nobutaka Mizoguchi; Tsuneo Tamaki; Nobukazu Fuwa
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-29       Impact factor: 7.038

4.  Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial.

Authors:  Jean Bourhis; Michel Lapeyre; Jacques Tortochaux; Michel Rives; Mehdi Aghili; Sylvain Bourdin; François Lesaunier; Toufik Benassi; Claire Lemanski; Lionel Geoffrois; Antoine Lusinchi; Pierre Verrelle; Etienne Bardet; Morbize Julieron; Pierre Wibault; Monique Luboinski; Ellen Benhamou
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

5.  18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma.

Authors:  Remy Lim; Anne Eaton; Nancy Y Lee; Jeremy Setton; Nisha Ohri; Shyam Rao; Richard Wong; Matthew Fury; Heiko Schöder
Journal:  J Nucl Med       Date:  2012-08-14       Impact factor: 10.057

6.  Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer.

Authors:  Man Ki Chung; Han-Sin Jeong; Sang Gyu Park; Jeon Yeob Jang; Young-Ik Son; Joon Young Choi; Seung Hyup Hyun; Keunchil Park; Myung-Ju Ahn; Yong Chan Ahn; Hyung-Jin Kim; Young-Hyeh Ko; Chung-Hwan Baek
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

Review 7.  Adjuvant therapy in patients with resected poor-risk head and neck cancer.

Authors:  Jacques Bernier; Jan B Vermorken; Wayne M Koch
Journal:  J Clin Oncol       Date:  2006-06-10       Impact factor: 44.544

8.  Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial.

Authors:  L J Peters; H Goepfert; K K Ang; R M Byers; M H Maor; O Guillamondegui; W H Morrison; R S Weber; A S Garden; R A Frankenthaler
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-04-30       Impact factor: 7.038

9.  Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer.

Authors:  Trang H La; Edith J Filion; Brit B Turnbull; Jackie N Chu; Percy Lee; Khoa Nguyen; Peter Maxim; Andy Quon; Edward E Graves; Billy W Loo; Quynh-Thu Le
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-14       Impact factor: 7.038

10.  Prognostic value of FDG PET imaging in patients with laryngeal cancer.

Authors:  Kazuhiro Kitajima; Yuko Suenaga; Tomonori Kanda; Daisuke Miyawaki; Kenji Yoshida; Yasuo Ejima; Ryohei Sasaki; Hirokazu Komatsu; Miki Saito; Naoki Otsuki; Ken-Ichi Nibu; Naomi Kiyota; Tsutomu Minamikawa; Kazuro Sugimura
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

View more
  7 in total

1.  NFBD1/MDC1 participates in the regulation of proliferation and apoptosis in human laryngeal squamous cell carcinoma.

Authors:  X Liu; Z Qiu; Z Wang; W Zuo; Z Gong; C Liu; Q Zeng; Y Qian; L Jiang; Y Li; Y Bu; G Hu
Journal:  Clin Transl Oncol       Date:  2017-09-18       Impact factor: 3.405

2.  Pretreatment 18F-FDG Uptake Heterogeneity Predicts Treatment Outcome of First-Line Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.

Authors:  Chengcheng Gong; Guang Ma; Xichun Hu; Yingjian Zhang; Zhonghua Wang; Jian Zhang; Yannan Zhao; Yi Li; Yizhao Xie; Zhongyi Yang; Biyun Wang
Journal:  Oncologist       Date:  2018-08-06

3.  Overall Neutrophil-to-Lymphocyte Ratio and SUVmax of Nodal Metastases Predict Outcome in Head and Neck Cancer Before Chemoradiation.

Authors:  Jonas Werner; Klaus Strobel; Dirk Lehnick; Gunesh P Rajan
Journal:  Front Oncol       Date:  2021-10-08       Impact factor: 6.244

4.  Utility and limitations of metabolic parameters in head and neck cancer: finding a practical segmentation method.

Authors:  Jefferson Rijo-Cedeño; Jorge Mucientes; Ithzel María Villarreal; Ana Royuela; Patricia García Vicente; José Ramón García-Berrocal
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-05-02       Impact factor: 3.236

5.  Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of 18F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer.

Authors:  Chengcheng Gong; Cheng Liu; Zhonghua Tao; Jian Zhang; Leiping Wang; Jun Cao; Yannan Zhao; Yizhao Xie; Xichun Hu; Zhongyi Yang; Biyun Wang
Journal:  Cancers (Basel)       Date:  2022-08-17       Impact factor: 6.575

6.  18F-Fluorodeoxyglucose Positron Emission Tomography of Head and Neck Cancer: Location and HPV Specific Parameters for Potential Treatment Individualization.

Authors:  Sebastian Zschaeck; Julian Weingärtner; Elia Lombardo; Sebastian Marschner; Marina Hajiyianni; Marcus Beck; Daniel Zips; Yimin Li; Qin Lin; Holger Amthauer; Esther G C Troost; Jörg van den Hoff; Volker Budach; Jörg Kotzerke; Konstantinos Ferentinos; Efstratios Karagiannis; David Kaul; Vincent Gregoire; Adrien Holzgreve; Nathalie L Albert; Pavel Nikulin; Michael Bachmann; Klaus Kopka; Mechthild Krause; Michael Baumann; Joanna Kazmierska; Paulina Cegla; Witold Cholewinski; Iosif Strouthos; Klaus Zöphel; Ewa Majchrzak; Guillaume Landry; Claus Belka; Carmen Stromberger; Frank Hofheinz
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

7.  FDG-PET predicts bone invasion and prognosis in patients with oral squamous cell carcinoma.

Authors:  Nan-Chin Lin; I-Hsien Su; Jui-Ting Hsu; Kuo-Yang Tsai; Michael Y C Chen
Journal:  Sci Rep       Date:  2021-07-26       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.